3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
143
Neoplasm Metastasis
16
Ovarian Neoplasms
6
Advanced Breast Cancer
6
Prostatic Neoplasms
5
Breast Cancer Metastatic
5
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Lobular
3
Lung Neoplasms
2
HER2-positive Breast Cancer
2
Exanthema
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms, Male
2
Triple Negative Breast Neoplasms
1
The Neoadjuvant Therapy
1
Stomach Neoplasms
1
Solid Tumor
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Sarcoma
1
Salivary Gland Neoplasms
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Neoplastic Cells, Circulating
1
Multiple Endocrine Neoplasia Type 1
1
Melanoma
1
Malignant Neoplasms of Female Genital Organs
1
Interventions
Insulin Glargine
4
Insulin
3
volagidemab
2
Metformin
2
Alpelisib
2
ziprasidone
1
olaparib
1
exemestane
1
Vildagliptin
1
Tamoxifen
1
Standard of Care
1
Olanzapine
1
Letrozole
1
Insulin Lispro
1
Insulin Aspart
1
Injections
1
Fulvestrant
1
DNA, Ribosomal
1
Control Groups
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hyperglycemia
×
Fulvestrant
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled